

ABSTRACT OF THE DISCLOSURE

Disclosed are methods for the isolation and purification of high-titer recombinant adeno-associated virus (rAAV) compositions. Also disclosed are methods for reducing or eliminating the concentration of helper adenovirus in rAAV samples. Methods are
5 disclosed that provide highly-purified rAAV stocks having titers up to about 10^{13} particles/ml at particle-to-infectivity ratios of less than 100 in processes that are accomplished about 24 hours or less.